Charles Schwab Investment Management Inc Finch Therapeutics Group, Inc. Transaction History

Charles Schwab Investment Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.75 - $51.3 $24,134 - $707,478	-13,791 Reduced 42.34%	18,783 $32,000
Q2 2022 Aug 15, 2022	SELL	$1.91 - $5.11 $42,738 - $114,341	-22,376 Reduced 40.72%	32,574 $93,000
Q1 2022 May 13, 2022	SELL	$5.02 - $10.47 $13,860 - $28,907	-2,761 Reduced 4.78%	54,950 $277,000
Q4 2021 Feb 11, 2022	BUY	$8.95 - $16.88 $36,981 - $69,748	4,132 Added 7.71%	57,711 $576,000
Q3 2021 Nov 16, 2021	BUY	$12.2 - $16.75 $51,276 - $70,400	4,203 Added 8.51%	53,579 $697,000
Q2 2021 Aug 16, 2021	BUY	$12.03 - $17.51 $593,993 - $864,573	49,376 New	49,376 $695,000

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $575M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.